

Research article

Open Access

The GCC repeat length in the 5'UTR of *MRP1* gene is polymorphic: a functional characterization of its relevance for cystic fibrosis

Elena Nicolis, Matteo Pasetto, Cristina Cigana, Ugo Pradal, Baroukh M Assael and Paola Melotti*

Address: Cystic Fibrosis Center, Azienda Ospedaliera di Verona, Piazzale Stefani 1, 37126 Verona, Italy

Email: Elena Nicolis - elenni@libero.it; Matteo Pasetto - biomatteo@tin.it; Cristina Cigana - cristinacgn@libero.it; Ugo Pradal - ugo.pradal@mail.azosp.vr.it; Baroukh M Assael - baroukh.assael@unimi.it; Paola Melotti* - paolamelotti@libero.it

* Corresponding author

Published: 07 February 2006

Received: 08 July 2005

BMC Medical Genetics 2006, **7**:7 doi:10.1186/1471-2350-7-7

Accepted: 07 February 2006

This article is available from: <http://www.biomedcentral.com/1471-2350/7/7>

© 2006 Nicolis et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Among the members of the ATP binding cassette transporter superfamily, MRPs share the closest homology with the CFTR protein, which is defective in CF disease. *MRP1* has been proposed as a potential modifier gene and/or as novel target for pharmacotherapy of CF to explain the clinical benefits observed in some CF patients treated with the macrolide AZM. The 5'UTR of the *MRP1* gene contains a GCC triplet repeat that could represent a polymorphic site and affect the activity of the promoter.

Methods: The *MRP1* 5' flanking region was amplified by PCR from 36 CF patients and 100 non-CF subjects and the number of GCC triplets of each allele was determined by sequence and electrophoretic analysis. We performed gene reporter studies in CF airway epithelial cells I6HBE14o-AS3, in basal conditions and in the presence of AZM.

Results: We found that the GCC repeat is polymorphic, ranging from 7 to 14 triplets either in CF or in non-CF subjects. Our data are preliminary and have to be confirmed on a larger population of CF subjects. The transcriptional activity of the proximal *MRP1* 5' regulatory region revealed no statistically significant correlations between the number of repeats and treatment with AZM.

Conclusion: We identified a novel polymorphism in the 5'UTR of *MRP1* gene that provides multiple alleles in a gene relevant for multidrug resistance as well as for CF, determining that this region is transcriptionally active and that this activity does not appear to be influenced by AZM treatment.

Background

CF is an autosomal recessive disease primarily manifested in the lung, which leads to respiratory failure. CF is caused by mutations of the *CFTR* gene whose product acts as a cAMP-activated chloride channel that is permeable to organic anions, including GSH [1,2]. A wide range of disease severities has been described, even among CF

patients harbouring the same mutation. Therefore endogenous factors, that modulate or complement CFTR function, must exist. Because of the structural homology between CFTR and MRP1, a functional complementation of CFTR defect by MRP1 has been hypothesized [3]. Induction of MRP1 expression has been suggested to be responsible for improvement in lung function in a CF

Table 1: *MRP1*(GCC)_n alleles frequencies in non-CF and CF subjects

Number of GCC triplets	Alleles in non-CF subjects (%)	Alleles in CF patients (%)
7	32	29
10	3	0
11	16	21
12	13	10
13	31	38
14	5	2

patient following chemotherapy with cyclophosphamide and epirubicin [4]. Low levels of *MRP1* transcripts have been associated with more severe CF phenotype [5], while increased expression of the *MRP1* gene has been associated with restored chloride conductance in a group of CF patients following treatment with AZM, giving rise to clinical beneficial effects [6,7]. *MRP1* has been considered as a potential modifier gene [5] and/or as a target for therapy of CF in subjects responsive to AZM [8].

The *MRP1* was originally cloned in a drug-selected lung cancer cell line [9]. MRPs are transmembrane proteins, whose mRNAs are detectable in most human tissues [10]. They share the closest homology with the CFTR protein, which belongs to the same C subfamily of the ABC transporter superfamily [11]. *MRP1* confers resistance to chemotherapeutic drugs as well as to heavy metal oxyanions. It transports reduced glutathione conjugates, cysteinyl leukotriene LTC₄, steroid glucuronides and bile salt derivatives in human cells, agents involved in the transcription factor NF-κB activation pathway, which has been reported to be altered in CF [12,13]. Therefore a functional link exists between genes involved in GSH metabolism and *MRP1*. NF-κB regulates expression of *GSTP1* and polymorphisms of the anti-oxidizing enzymes *GSTP1* and *GSTM3* are associated with severity of CF [14]. The *GSTM1* gene, encoding an enzyme that forms glutathione adducts, is deleted in most severe CF patients [15]. CF patients carrying a wild type allele for both *GSTM1* and *GSTT1* may be at reduced risk of severe lung disease. The abnormal reduced glutathione transport caused by CFTR mutation seems to play a critical role in the pathogenesis of CF and this parameter might also be complemented by *MRP1* in CF patients. *MRP1* has been also involved in the regulation of endogenous channels as chloride channels [16,17]. The physiological functions of *MRP1* are the subject of many current investigations: the available evidence indicates that it is involved in detoxification, drug resistance, oxidative stress and inflammation [18,19]. An impaired response to inflammatory stimuli has been described in *MRP1*(-/-) knockout mice [20], even if *MRP1* has not been demonstrated to be a disease-causing gene.

The sequence of the *MRP1* gene has been reported [9]. The 5' flanking region is GC rich (88%) while the 5'UTR contains a GCC triplet repeat that has been hypothesized to represent a polymorphic site [12]. The influence of the number of triplets in the 5'UTR on *MRP1* mRNA transcription, stability and translational efficiency has not been determined.

We searched a genetic marker for *MRP1* with potential functional relevance aiming to establish: 1) whether the GCC repeat in the *MRP1* 5'UTR is polymorphic, 2) if the GCC triplets length could affect the activity of the promoter in CF airways epithelial cells either in basal conditions or upon AZM treatment.

Methods

Patients and controls

Genomic DNA from 100 unrelated non-CF subjects and 36 CF patients was collected. Nucleic acid was extracted from peripheral blood leukocytes using the salting out method [21]. Diagnosis of CF was based on clinical, biochemical and genetic data. The most common CF causing mutation, deltaF508, was detected in 24 patients, 7 of which were homozygous. This study was approved by the local institutional Ethic Committee.

Genotyping

Specific primers were designed based on the nucleotide sequence of the 5' regulatory region of *MRP1* gene (GenBank:U07050) (sequences are available upon request). PCRs were performed in an Applied Biosystems 9700 Thermal Cycler, using a final volume of 50 μl. Due to the high GC levels of the PCR products, 7-deaza-dGTP (Roche) was utilized instead of dGTP in the dNTPs mix. PCR-1 started with 350 ng of genomic DNA; 2.5 μl of PCR-1 were subjected to further amplification (PCR-2) and a third round of amplification (PCR-3) was performed with 2.5 μl of PCR-2. Amplifications were carried out starting with 10 min template denaturation/AmpliTaQ Gold (Applied Biosystems) activation step at 95°C, followed by 40 cycles (20 cycles for PCR-3) of denaturation at 95°C for 30 s, annealing at 58°C for 30 s and extension

Table 2: Genotypes frequencies of the *MRP1*(GCC)*n* alleles in the control group and in the CF patients

Genotype	% in non-CF subjects	% in CF subjects
7/7	23	25
13/13	15	6
7/13	12	0
11/12	10	11
11/13	9	0
12/13	7	28
7/11	5	6
12/12	4	3
11/11	3	0
14/14	3	0
10/11	2	8
10/13	2	0
10/14	2	0
13/14	2	2
7/14	1	0
12/14	0	8
7/12	0	3

at 72 °C for 30 s. As a final product the fragment from -337 nt to -43 nt, starting from the translational starting site of the *MRP1* 5' gene, was obtained.

PCR products were purified with the NucleoSpin Extract kit (Macherey-Nagel). Samples were then sequenced using Thermo Sequenase II Dye Terminator Cycle Sequencing Premix Kit (Amersham Biosciences) and the automated 373A DNA Sequencer (Applied Biosystems).

PCR-3 was carried out in the presence of a primer conjugated to FAM dye (5-carboxyfluorescein) (Applied Biosystems) that generated labelled amplicons suitable for electrophoresis and Genescan analysis.

Genescan analysis Software (Applied Biosystems) was used to determine the length of the PCR products. In order to validate our method we utilized a vector including the *MRP1* (GCC)7 allele (kind gift from Roger Deeley, Queen's University, Kingston, Ontario, Canada) as control. A proof-reading enzyme was utilized and at least duplicates of each sample and control vector were performed to exclude polymerase slippage.

Gene reporter studies

The *MRP1* 5' regulatory region containing 7 or 14 GCC triplets, obtained as PCR-3 product, was cloned in the pGL3 vector (Promega). The constructs were checked by restriction, sequence and Genescan analysis and named *MRP1*(GCC)7-luc or *MRP1*(GCC)14-luc, according to the number of triplets. The CF airway epithelial cell line 16HBE14o-AS3 (kind gift from Pamela Davis, Case Western Reserve University School of Medicine, Cleveland, OH, USA) was transiently co-transfected using FUGENE (Roche) with the reporter vector *MRP1*(GCC)7-luc or

MRP1(GCC)14-luc and a beta-galactosidase expressing vector, utilized for normalization. The day after the transfection, cells were incubated for 24 hrs with or without AZM 8 µg/ml (Pfizer Italia). This concentration is consistent with that achieved in the lung of CF patients treated with AZM [22]. Luciferase activity was determined using the Luciferase Assay System (Promega) according to the manufacturer's instructions. Luciferase activity in insert-less (pGL3) transfected cells was almost undetectable.

Results

The *MRP1* 5' flanking region is polymorphic

The *MRP1* 5' flanking region was amplified by PCR from 36 CF patients and 100 non-CF subjects and the number of triplets of each allele was determined by sequencing and electrophoretic analysis.

In non-CF subjects the number of triplets ranged from 7 triplets to 14. Six distinct alleles consisting of 7, 10, 11, 12, 13 and 14 GCC triplets were found. The frequencies of these *MRP1*(GCC)*n* alleles, where *n* indicates the number of triplets, is shown in Table 1. The genotypes frequencies of the GCC alleles are indicated in Table 2.

Assessment of transcriptional activity

In order to establish whether the length of the GCC repeat can affect the transcriptional activity we performed gene reporter studies in CF airway epithelial cells 16HBE14o-AS3. This region has been previously demonstrated to be transcriptionally active by gene reporter studies [9]. Since the clinical status as well as the response to AZM has been associated to the levels of *MRP1* mRNA in CF patients, we tested the transcriptional activity of *MRP1* in our model by gene reporter assays in the presence or absence of the drug. The levels of luciferase activity measured in the con-




Figure 1
Comparison of the transcriptional activity of MRP1 alleles containing 7 or 14 GCC triplets. 16HBE14o-AS3 cells were transfected with reporter vectors including the *MRP1* 5'UTR region with 7 [MRP1(GCC)7-luc] or 14 triplets [(GCC)14-luc] driving the luciferase gene. 16HBE14o-AS3 cells transfected with MRP1(GCC)7-luc and not treated with AZM were considered as calibrator. Percentages of luciferase activity normalized with beta galactosidase are shown. Specificity of the signal was assessed by determining the luciferase activity in insert-less (pGL3) transfected cells, which was almost undetectable. Experiments were performed in triplicate ($n = 3$, $p > 0.05$ for all conditions, paired T-Test; SEMs are indicated by bars).

structs containing 7 or 14 GCC triplets of the *MRP1* 5' regulatory region were not significantly modified ($p > 0.05$) either in basal conditions or in the presence of AZM (Figure 1).

Discussion

This study demonstrates that the genomic region from -337 nt to -43 nt of the *MRP1* 5' regulatory region includes a polymorphic site and possesses transcriptional activity. We also demonstrate that the *MRP1*(GCC)7 and *MRP1*(GCC)14 alleles (chosen as representative of the shortest and longest triplet length we identified) do not show any statistically significant differences in transcriptional activity when tested in CF airway epithelial cells *in vitro*. We chose these two alleles since we hypothesized that the length of the GCC repeat could influence *MRP1* transcriptional activity as suggested by other authors [9]. Since we have been focusing to a partial region of the 5'UTR of the *MRP1* gene, our approach was not aimed to test the influence of upstream regulatory sites eventually associated with specific GCC(n) alleles, as a recently described G/C single nucleotide polymorphism [23].

The number of alleles described in our limited group of CF subjects does not allow for searching genotype-phenotype correlation. Efforts are in progress in order to perform this analysis. Our data are preliminary and have to be confirmed on a larger population of CF subjects.

We show that AZM treatment does not affect reporter gene activity in either of the tested alleles. Therefore, at least under the experimental conditions we utilized in our assays, the sequence responsible for variable levels of *MRP1* detected in other studies [5,8] does not appear to be included in the DNA sequence we analyzed. Previous studies reported that multiple Sp-1 binding domains are located close to *MRP1* transcriptional start sites near the GCC repeat and might participate in the modulation of transcriptional activity. Zhu and Center [9] suggested a variable length of the GCC repeat in the *MRP1* 5' regulatory region and proposed the influence of this sequence on the *MRP1* mRNA transcription. In support of this hypothesis, it has been reported that a triple GCC repeat within the 5' flanking region contributes to the regulation of interleukin 1 alpha expression [24]. As Slapak and colleagues demonstrated that *MRP1* gene amplification is not sufficient for explaining drug resistance [25], the polymorphism we identified might be utilized for investigating whether the number of GCC triplets could be associated with this feature. However, we still cannot exclude a functional relevance of this polymorphism on *MRP1* mRNA transcription, stability and/or translational efficiency in its native context.

Conclusion

In summary we established that: 1) the GCC repeat in the *MRP1* 5'UTR is polymorphic, 2) the GCC triplets length do not affect *in vitro* the activity of the promoter in CF airways epithelial cells either in basal conditions or upon AZM treatment.

We propose our experimental for testing whether other molecules potentially relevant for therapy of CF have the capability to influence *MRP1* gene expression acting on this promoter region.

Finally, the polymorphic length of the GCC repeat we described can be exploited as a genetic marker, possibly linked to additional sequences involved in regulation of constitutive or induced *MRP1* expression.

List of abbreviations

AZM azithromycin

CF cystic fibrosis

CFTR cystic fibrosis transmembrane conductance regulator

GST glutathione S transferase

MRP multidrug resistance-associated protein

UTR untranslated region

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

EN designed and provided the genotyping method and contributed to the redaction of the manuscript. MP performed the gene reporter analysis and contributed to genotyping. CG participated in the molecular genetic studies. UP collected the clinical data and provided clinical material. BA was involved in supervision of the work. PM designed, coordinated the study and drafted the manuscript.

All authors read and approved the final manuscript.

Acknowledgements

We thank the CF patients and non-CF subjects that made this study possible. We are grateful to all the personnel in charge of DNA banking at the Cystic Fibrosis Center of Verona, Italy. This study was supported by Italian Cystic Fibrosis Research Foundation and Legge 548/93 Finanziamento Ricerca Fibrosi Cistica 2004

References

- Lindsell PJ: **Glutathione permeability of CFTR**. *Am J Physiol* 1998, **275**:C323.
- Gao LKK, Yankaskas JR, Forman HJ: **Abnormal glutathione transport in cystic fibrosis airway epithelia**. *Am J Physiol* 1999, **277**:L113.
- Altschuler EL: **Azithromycin, the multidrug-resistant protein, and cystic fibrosis**. *Lancet* 1998, **351**:1286.
- Lallemand JY, Stoven V: **Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis?** *Lancet* 1997, **350**:711-712.
- Hurbain I, Sermet-Gaudelus I: **Evaluation of MRP1-5 gene expression in cystic fibrosis patients homozygous for the delta F508 mutation**. *Pediatr Res* 2003, **54**:627-634.
- Pradal U, Cipolli M, Cazzola G: **Chloride transport may be restored by long-term azithromycin treatment in patients with cystic fibrosis**. *Pediatr Pulmonol* 2000:280.
- Pradal U, Delmarco A: **Long term azithromycin in cystic fibrosis: another possible mechanism of action?** *J Chemother* 2005, **17**:384-400.
- Pradal U, Delmarco A: **Azithromycin induces over-expression of multidrug resistance-associated protein (MRP) and restores chloride conductance in cystic fibrosis [abstract]**. *J Cystic Fibrosis* 2002, **1**:s52.
- Zhu Q, Center MS: **Cloning and sequence analysis of the promoter region of the MRP gene of HL60 cells isolated for resistance to adriamycin**. *Cancer Res* 1994, **54**:4488-4492.
- Kruh GD, Gaughan KT: **Expression pattern of MRP in human tissues and adult solid tumor cell lines**. *J Natl Cancer Inst* 1995, **87**:1256-1258.
- Dean M, Rzhetsky A: **The human ATP-binding cassette (ABC) transporter superfamily**. *Genome Res* 2001, **11**:1156-1166.
- Loe DW, Deeley RG: **Biology of the multidrug resistance-associated protein, MRP**. *Eur J Cancer* 1996, **32A**:945-957.
- Venkatakrishnan ASA, King G, Blackwell TR, Bringham KL, Christman JW, Blackwell TS: **Exaggerated activation of NF- κ B and altered I κ B-beta processing in cystic fibrosis bronchial epithelial cells**. *American Journal of Respiratory Cell Molecular Biology* 2000, **23**:396-403.
- Henrion A, Flamant C, Roussey M, Strange RC, Chadelat K, Clement A: **Severity of cystic fibrosis is associated with gene polymorphism of anti-oxidizing enzymes [abstract]**. *Pediatr Pulmonol* 2001, **22**:s215.
- Baranov VS, Bakay B, Aseev M, Belotserkovskaya R, Baranova H, Malet P, Perriot J, Mouraire P, Baskakov VN, Savitskiy GA, Gorbushin S, Deyneka SI, Michnin E, Barchuck A, Vakhharlovsky V, Pavlov G, Shilko VI, Guembitzkaya T, Kovaleva L: **Proportion of the GSTM1 0/0 genotype in some Slavic populations and its correlation with cystic fibrosis and some multifactorial diseases**. *Hum Genet* 1996, **97**:516-520.
- Jirsch JR, Deeley G: **Inwardly rectifying K⁺ channels and volume-regulated anion channels in multidrug-resistant small cell lung cancer cells**. *Cancer Res* 1993, **53**:4156-4160.
- Hainsworth AH, Henderson RM: **Hypotonicity-induced anion fluxes in cells expressing the multidrug-resistance-associated protein, MRP**. *Pflugers Arch* 1996, **432**:234-240.
- Borst P, Kool RE, Wijnholds M: **A family of drug transporters: the multidrug resistance-associated proteins**. *J Natl Cancer Inst* 2000, **92**:1295-1302.
- Leslie EM, Cole SP: **Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters**. *Toxicology* 2001, **67**:3-23.
- Wijnholds J, van Leudsen MR, Mol CA, Zaman GJ, Mayer U, Beijnen J, der Valk M, Krimpenfort P, Borst P: **Increased sensitivity to anti-cancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein**. *Nat Med* 1997, **3**:1275-1279.
- Miller SA, Dykes DD: **A simple salting out procedure for extracting DNA from human nucleated cells**. *Nucleic Acids Res* 1988, **16**:1215.
- Cipolli M, Novelli G, Cassetta MI, Fallani S, Mazzei T: **Azithromycin concentrations in serum and bronchial secretions of patients with cystic fibrosis**. *Clin Drug Invest* 2001, **21**:353.
- Wang Z, Wang B, Tang K, Lee EJD, Chong SS, Lee CGL: **A functional polymorphism within the MRP1 gene locus identified through its genomic signature of positive selection**. *Hum Mol Gen* 2005, **14**:2075-2087.
- Zaldivar F, Nugent DJ: **Identification of a novel regulatory element in the human interleukin 1 alpha (IL-1alpha) gene promoter**. *Cytokine* 2002, **20**:130-135.
- Slapak CA, Fracasso PM, Martell RL, Toppmeyer DL, Lecerf JM, Levy SB: **Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells**. *Cancer Res* 1994, **54**:5607-5613.

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2350/7/7/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

